March 20, 2015

Zijin Mining Group

2014 Result No Major Surprise

Industry View Stock Rating **Attractive** Overweight

Quick Comment: Zijin reported 2014 net profit of Rmb2,346mn or Rmb0.11/shr, +10% YoY. Implied 4Q14 profit was Rmb0.017/sh. This is in line with the preliminary result the company announced on February 16. Zijin declared a final dividend of Rmb0.08/share, representing a 74% payout and a 4.5% dividend yield for H share (A share: 2.1%).

2014 results details:

- **Sales volume:** Sales volumes for most products werer generally in line with our estimates. Refined gold sales volume climbed 62% YoY, more than expected, while mined zinc missed the company's previous target by 40%, (See Exhibit 1.)
- **ASP**: Except for mined and refined zinc, ASP for all other products declined YoY. Mined gold and copper ASPs fell 13% and 9% YoY, respectively. However, revenue still rose 18% YoY due to refined gold volume growth. Revenue was in line with our estimate at Rmb58,761mn.
- Cost: Zijin reduced unit costs for almost all products, especially precious metals, where mined and refined gold unit costs fell 18% and 10%, respectively. Mine copper unit cost was up 3% YoY.
- Gross profit margin: Due to an increase low-margin refined gold volume, the gross margin dropped 4.5% to 12%.
- Capex: Management guided for Rmb2.2bn capex in 2015 (excluding US\$180mn to be spent on Congo gold and copper mine project) and another Rmb10bn on future M&A (management mentioned the amount has uncertainty). These expenditures will be financed by internal cash flow, bank loans, medium-term notes, etc.
- **2015 production guidance:** Management targets a 7-8% growth in mined gold, copper and iron ore, and more than double production volume of 2015e mined zinc. 2015 mined gold production guidance of 36t is 1.1% higher than we expected. Mined copper volume guidance of 150kt is 25% below our forecast. Zinc volume guidance of 210kt is 5% higher than our previous forecast.

Results briefing: March 23, 10:15. Island Shangri-La

MORGAN STANLEY ASIA LIMITED+ Rachel L Zhang Rachel.Zhang@morganstanley.com +852 2239-1520 Ada Gao, CFA Ada.Gao@morganstanley.com +852 2239-7810 Sara Chan Sara.Chan@morganstanley.com +852 2848-5292

Stock Rating	Overweigh
Industry View	Attractive
Shr price, close (Mar 20, 2015)	HK\$2.19
52-Week Range	HK\$2.65-1.59
Sh out, dil, curr (mn)	5,896
Mkt cap, curr (mn)	Rmb72,010
EV, curr (mn)	Rmb95,838
Avg daily trading value (mn)	HK\$62

Fiscal Year Ending	12/13	12/14e	12/15e	12/16e
ModelWare EPS (Rmb)	0.10	0.12	0.20	0.20
Prior ModelWare EPS (Rmb)	-	-	-	-
Consensus EPS (Rmb)§	0.11	0.11	0.12	0.13
Revenue, net (Rmb mn)	49,052	54,838	55,423	57,252
EBITDA (Rmb mn)	8,018	7,209	10,453	11,025
ModelWare net inc	2,125	2,685	4,352	4,321
(Rmb mn)				
P/E	13.2	14.2	8.6	8.7
P/BV	1.0	1.3	1.1	1.0
RNOA (%)	8.7	7.3	9.9	9.3
ROE (%)	7.5	9.7	14.4	12.5
EV/EBITDA	8.5	12.7	9.5	8.8
Div yld (%)	0.0	0.0	0.0	0.0
FCF yld ratio (%)	(4.4)	(10.8)	0.7	6.3
Leverage (EOP) (%)	37.0	45.7	36.8	24.5

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework $\S=$ Consensus data is provided by Thomson Reuters Estimates

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Morgan Stanley

Exhibit 1: Zijin 2014 Result Snapshot

(Rmb million)	2014	MSe	diff %	YoY
Operation data				
Mined gold ASP	232	251	-8%	-5%
Mined copper ASP (Rmb/t)	35,804	37,886	-5%	-6%
Sales volume				
Mine-produced gold (kg)	33,776	34,000	-1%	5%
Refinery gold (kg)	125,093	106,788	17%	62%
Mine-produced Silver(Kg)	171,617	163,771	5%	9%
Mine-produced copper (t)	136,838	140,000	-2%	9%
Refined copper (t)	235,150	220,000	7%	13%
Mine produced zinc (t)	96,416	160,000	-40%	28%
Refinery zinc (t)	207,303	200,000	4%	14%
Iron ore (t)	2,800,000	3,108,667	-10%	7%
Financial data				
Revenue	58,761	58,752	0%	18%
Gross profit	7,040	9,389	-25%	-14%
Gross margin	12%	16%	-4.0 ppt	-4.5 ppt
EBITDA	6,716	8,856	-24%	-2%
EBITDA margin	11%	15%	-3.6 ppt	-2.3 ppt
EBIT	4,071	4,842	-16%	-9%
EBIT margin	7%	8%	-1.3 ppt	-2.0 ppt
Net income	2,346	2,346	0%	10%
Net margin	4%	4%	0.0 ppt	-0.3 ppt
EPS (Rmb)	0.11	0.12	-13%	11%

Source: Company data, Morgan Stanley Research

Exhibit 2: Zijin 4Q14 Operating Data by Product

		ASP			Unit cost		
	Unit	2014	2013	YoY	2014	2013	YoY
Mine-produced gold	Rmb/g	232	266	-13%	144	152	-6%
Refinery gold	Rmb/g	249	274	-9%	248	275	-10%
Mine-produced Silver	Rmb/g	3.99	na	na	1.62	1.76	-8%
Mine-produced copper	Rmb/t	35,804	39,422	-9%	18,467	17,908	3%
Refined copper	Rmb/t	41,872	45,155	-7%	41,391	45,861	-10%
Mine produced zinc	Rmb/t	8,146	7,570	8%	3,509	3,862	-9%
Refinery zinc	Rmb/t	13,612	12,881	6%	12,971	12,519	4%
Iron concentrates	Rmb/t	535	631	-15%	189	213	-11%

Source: Company data, Morgan Stanley Research

Exhibit 3: 2015 Production Guidance

Production volume					
		2015	2014		
	Unit	Target	actual	YoY	
Mine-produced gold	kg	36,000	33,727	7%	
Mine-produced copper	t	150,000	138,462	8%	
Mine produced zinc	t	210,000	96,261	118%	
Iron concentrates	mnt	3.00	2.80	7%	

Source: Company data, Morgan Stanley Research

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited, and/or PT Morgan Stanley Asia Indonesia and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any price targets referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Sara Chan, Ada Gao, Rachel Zhang.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

Important US Regulatory Disclosures on Subject Companies

As of February 27, 2015, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Jianoxi Copper, Maanshan Iron & Steel.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Angang Steel Company Limited, G-Resources, Jiangxi Copper, Lee & Man Paper Manufacturing, **Zijin Mining Group**.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from G-Resources, **Zijin Mining Group**.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Angang Steel Company Limited, G-Resources, Jiangxi Copper, Lee & Man Paper Manufacturing, **Zijin Mining Group**. Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Baoshan Iron & Steel, G-Resources, Jiangxi Copper, **Zijin Mining Group**.

Morgan Stanley & Co. LLC makes a market in the securities of Aluminum Corp. of China Ltd..

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of February 28, 2015)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

	COVERAGE UNIVERSE		INVESTMENT BANKING CLIENTS (IBC)		
STOCK RATING CATEGORY	COUNT	% OF TOTAL	COUNT	% OF TOTAL	% OF RATING
				IBC	CATEGORY
Overweight/Buy	1161	35%	321	41%	28%
Equal-weight/Hold	1459	44%	370	47%	25%
Not-Rated/Hold	101	3%	10	1%	10%
Underweight/Sell	609	18%	88	11%	14%
TOTAL	3,330		789		

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views


Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)



Source: Morgan Stanley Research Date Format: MM/DD/YY Price Target - No Price Target Assigned (NA)
Stock Price (Not Covered by Current Analyst) - Stock Price (Covered by Current Analyst) - Stock and Industry Ratings (abbreviations below) appear as \$ Stock Rating/Industry View
Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)
Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

MORGAN STANLEY RESEARCH

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments. To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Bank Morgan Stanley AG, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Bank Morgan Stanley AG, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" within the meaning of the Australian

Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Indonesia by PT Morgan Stanley Asia Indonesia; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Conduct Authority, also disseminates Morgan Stanley Research in the UK. Private UK investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations. The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P. Morgan Stanley Research or portions of it may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

INDUSTRY COVERAGE: China Materials

COMPANY (TICKER)	RATING (AS OF)	PRICE* (03/20/2015)
Lam CFA, John		
Lee & Man Paper Manufacturing (2314.HK) Nine Dragons Paper (2689.HK)	U (07/01/2014) U (07/01/2014)	HK\$3.72 HK\$5.05
Zhang, Rachel L		
Auminum Corp. of China Ltd. (601600.SS) Aluminum Corp. of China Ltd. (2600.HK) Angang Steel Company Limited (0347.HK) Angang Steel Company Limited (000898.SZ) Baoshan Iron & Steel (600019.SS) Chinalco Mning Corp International (3668.HK) G-Resources (1051.HK) Jiangxi Copper (0358.HK) Jiangxi Copper (600362.SS) Jilin Jien Nickel Industry (600432.SS) Maanshan Iron & Steel (0323.HK) Maanshan Iron & Steel (600808.SS) Zhaojin Mning Industry (1818.HK) Zijin Mning Group (601899.SS) Zijin Mning Group (2899.HK)	E (12/16/2014) O (12/16/2014) O (11/28/2013) O (08/30/2014) O (03/31/2014) E (06/18/2014) E (10/07/2013) E (10/08/2014) E (12/19/2014) C (12/16/2014) O (12/16/2014) O (01/20/2015) E (01/20/2015)	Rmb6.34 HK\$3.61 HK\$5.26 Rmb6.03 Rmb6.84 HK\$0.23 HK\$13.36 Rmb19.63 Rmb19.63 Rmb19.63 Rmb18.20 HK\$2.06 Rmb3.97 HK\$4.29 Rmb3.88 HK\$2.19

Stock Ratings are subject to change. Please see latest research for each company.

© 2015 Morgan Stanley

^{*} Historical prices are not split adjusted.